BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 28877609)

  • 21. Cytoreductive Surgery (CRS) Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Platinum-Sensitive Recurrence Epithelial Ovarian Cancer With HRR Mutation: A Phase III Randomized Clinical Trial.
    Qi Y; Zhang Y; Shi Y; Yao S; Dai M; Cai H
    Technol Cancer Res Treat; 2022; 21():15330338221104565. PubMed ID: 35929135
    [No Abstract]   [Full Text] [Related]  

  • 22. Oxaliplatin-based hyperthermic intraperitoneal chemotherapy in primary or recurrent epithelial ovarian cancer: A pilot study of 31 patients.
    Frenel JS; Leux C; Pouplin L; Ferron G; Berton Rigaud D; Bourbouloux E; Dravet F; Jaffre I; Classe JM
    J Surg Oncol; 2011 Jan; 103(1):10-6. PubMed ID: 21031424
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: a multicenter, prospective study of 246 patients.
    Bakrin N; Cotte E; Golfier F; Gilly FN; Freyer G; Helm W; Glehen O; Bereder JM
    Ann Surg Oncol; 2012 Dec; 19(13):4052-8. PubMed ID: 22825772
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Morbidity and mortality outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with primary and recurrent advanced ovarian cancer.
    Cascales Campos P; Gil J; Parrilla P
    Eur J Surg Oncol; 2014 Aug; 40(8):970-5. PubMed ID: 24035502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-Term Survival for Platinum-Sensitive Recurrent Ovarian Cancer Patients Treated with Secondary Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
    Petrillo M; De Iaco P; Cianci S; Perrone M; Costantini B; Ronsini C; Scambia G; Fagotti A
    Ann Surg Oncol; 2016 May; 23(5):1660-5. PubMed ID: 26714958
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value and adverse events of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in primary advanced and platinum-sensitive recurrent epithelial ovarian cancer: a systematic review and meta-analysis.
    Xia Y; Wang H; Zhang J; Wang Y
    Int J Hyperthermia; 2023; 40(1):2165729. PubMed ID: 36775583
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Routine ureteric stenting before cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in managing peritoneal carcinomatosis from gynecologic malignancies: a single-center experience.
    Abu-Zaid A; Abou Al-Shaar H; Azzam A; AlOmar O; Al-Otaibi MF; Amin T; Al-Badawi IA
    Ir J Med Sci; 2017 May; 186(2):269-273. PubMed ID: 27052968
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial.
    Lim MC; Chang SJ; Park B; Yoo HJ; Yoo CW; Nam BH; Park SY;
    JAMA Surg; 2022 May; 157(5):374-383. PubMed ID: 35262624
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytoreduction (Peritonectomy Procedures) Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Advanced Ovarian Cancer: Retrospective Italian Multicenter Observational Study of 511 Cases.
    Di Giorgio A; De Iaco P; De Simone M; Garofalo A; Scambia G; Pinna AD; Verdecchia GM; Ansaloni L; Macrì A; Cappellini P; Ceriani V; Giorda G; Biacchi D; Vaira M; Valle M; Sammartino P
    Ann Surg Oncol; 2017 Apr; 24(4):914-922. PubMed ID: 27896512
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Minimally invasive secondary cytoreduction plus HIPEC versus open surgery plus HIPEC in isolated relapse from ovarian cancer: a retrospective cohort study on perioperative outcomes.
    Fagotti A; Costantini B; Gallotta V; Cianci S; Ronsini C; Petrillo M; Pacciani M; Scambia G; Fanfani F
    J Minim Invasive Gynecol; 2015; 22(3):428-32. PubMed ID: 25461683
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of intraoperatively detected peritoneal carcinomatosis of colorectal origin with cytoreductive surgery and intraperitoneal chemotherapy.
    Canda AE; Arslan C; Terzi C; Sokmen S; Yavuzsen T; Ozkardesler S; Unlu M; Obuz F; Fuzun M
    World J Surg Oncol; 2018 Mar; 16(1):70. PubMed ID: 29587771
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Peritonectomy procedures and HIPEC in the treatment of peritoneal carcinomatosis from ovarian cancer: Long-term outcomes and perspectives from a high-volume center.
    Muñoz-Casares FC; Medina-Fernández FJ; Arjona-Sánchez Á; Casado-Adam Á; Sánchez-Hidalgo JM; Rubio MJ; Ortega-Salas R; Muñoz-Villanueva MC; Rufián-Peña S; Briceño FJ
    Eur J Surg Oncol; 2016 Feb; 42(2):224-33. PubMed ID: 26673283
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytoreductive surgery and intraperitoneal chemo-hyperthermia for chemo-resistant and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients.
    Cotte E; Glehen O; Mohamed F; Lamy F; Falandry C; Golfier F; Gilly FN
    World J Surg; 2007 Sep; 31(9):1813-1820. PubMed ID: 17629740
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Validation of a peritoneal surface disease severity score in stage IIIC-IV ovarian cancer treated with cytoreduction and hyperthermic intraperitoneal chemotherapy.
    Pedro Antonio CC; Álvaro Jesús GR; José G; Elena G; Alida G; Francisco ML; Guillermo CDC; Pascual P
    Surg Oncol; 2019 Mar; 28():57-61. PubMed ID: 30851912
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis.
    Vassos N; Förtsch T; Aladashvili A; Hohenberger W; Croner RS
    World J Surg Oncol; 2016 Feb; 14(1):42. PubMed ID: 26912149
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for First Relapse of Ovarian Cancer.
    Classe JM; Glehen O; Decullier E; Bereder JM; Msika S; Lorimier G; Abboud K; Meeus P; Ferron G; Quenet F; Marchal F; Gouy S; Pomel C; Pocard M; Guyon F; Bakrin N;
    Anticancer Res; 2015 Sep; 35(9):4997-5005. PubMed ID: 26254399
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of CytoReductive surgery plus hyperthermic IntraPEritoneal chemotherapy (HIPEC) versus CytoReductive surgery for ovarian cancer patients: A systematic review and meta-analysis.
    Wang Y; Ren F; Chen P; Liu S; Song Z; Ma X
    Eur J Surg Oncol; 2019 Mar; 45(3):301-309. PubMed ID: 30786961
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Timing of Systemic Chemotherapy in Patients With Colorectal Peritoneal Carcinomatosis Treated With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    van Eden WJ; Kok NF; Jóźwiak K; Lahaye ML; Beets GL; van Leerdam ME; Boot H; Aalbers AG
    Dis Colon Rectum; 2017 May; 60(5):477-487. PubMed ID: 28383447
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heated IntraPEritoneal Chemotherapy (HIPEC) for Patients With Recurrent Ovarian Cancer: A Systematic Literature Review.
    Hotouras A; Desai D; Bhan C; Murphy J; Lampe B; Sugarbaker PH
    Int J Gynecol Cancer; 2016 May; 26(4):661-70. PubMed ID: 26844612
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rationale and study design of the CHIPPI-1808 trial: a phase III randomized clinical trial evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) for stage III ovarian cancer patients treated with primary or interval cytoreductive surgery.
    El Hajj H; Vanseymortier M; Hudry D; Bogart E; Abdeddaim C; Leblanc E; Le Deley MC; Narducci F
    ESMO Open; 2021 Apr; 6(2):100098. PubMed ID: 33819750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.